Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology—Retrospective insights from ATHENA 2020
2020 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors 2020
2020 Challenges Associated With Cervical Cancer Screening and Management in Obese Women: A Provider Perspective 2020
2020 Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) 2020
2020 Extensive financial hardship among gynecologic cancer patients starting a new line of therapy 2020
2020 Human papillomavirus vaccination: Ongoing challenges and future directions 2020
2020 Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008) 2020
2020 Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers 2020
2020 The Reliability of Intraoperative Assessment on Predicting Tumor Size, Myometrial Invasion, and Cervical Involvement in Patients with a Preoperative Diagnosis of Complex Atypical Hyperplasia or (Clinical Stage I) Endometrial Cancer: A Prospective Cohort Study 2020
2020 Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: An NRG Oncology Group study 2020
2019 Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread 2019
2019 Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report 2019
2019 The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up 2019
2019 Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012)) 2019
2019 Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population 2019
2019 The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up 2019
2019 Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial 2019
2019 Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution 2019
2019 Observed Colposcopy Practice in US Community-Based Clinics: The Retrospective Control Arm of the IMPROVE-COLPO Study 2019
2019 Cervical cancer, version 3.2019 2019
2019 Gestational trophoblastic neoplasia, version 2.2019 2019
2019 The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction 2019
2018 Catch-up human papillomavirus vaccination: don't throw the baby out with the bathwater 2018
2018 Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections 2018
2018 Access to gynecologic oncology care and the network adequacy standard 2018
2018 Financial toxicity – An overlooked side effect 2018
2018 High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women with Low-Grade Cervical Cytology 2018
2018 In Defense of a Simplified, Practical Colposcopic Terminology 2018
2018 Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study 2018
2018 Where are the opportunities for reducing health care spending within alternative payment models? 2018
2018 Lessons learned from domestic and international human papillomavirus vaccination programs: a review 2018
2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma 2018
2018 Lessons Learned from Domestic and International Human Papillomavirus Vaccination Programs: A Review 2018
2018 Uterine Neoplasms, Version 1.2018: Clinical practice guidelines in oncology 2018
2018 A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer 2018
2018 Feasibility of complete salpingectomy compared with standard postpartum tubal ligation at cesarean delivery a randomized controlled trial 2018
2018 HPV vaccination 2018
2018 Human Papillomavirus Genotypes from Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age 2018
2017 Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial 2017
2017 ASCCP Colposcopy Standards: Colposcopy Quality Improvement Recommendations for the United States 2017
2017 ASCCP Colposcopy Standards: How Do We Perform Colposcopy? Implications for Establishing Standards 2017
2017 ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice 2017
2017 ASCCP Colposcopy Standards: Role of Colposcopy, Benefits, Potential Harms, and Terminology for Colposcopic Practice 2017
2017 Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States 2017
2017 The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis 2017
2017 CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ACRIN and GOG study 2017
2017 Optimizing secondary prevention of cervical cancer: Recent advances and future challenges 2017
2017 Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials 2017
2017 Protection against cervical cancer versus decreasing harms from screening — What would U.S. patients and clinicians prefer, and do their preferences matter? 2017
2017 Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines 2017
2017 Transitioning from HPV 101 to HPV 202 2017
2017 Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States 2017
2017 Vulvar cancer, version 1.2017: Clinical practice guidelines in oncology 2017
2016 Cervical cancer screening: How do we make sense of it all and what is the right balance? 2016
2016 Expression of p16INK4A in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines 2016
2016 Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region 2016
2016 Drawing the Line in Risk-Reducing Gynecologic Surgery in Women with a BRCA Mutation 2016
2016 Trends in Colposcopy Volume: Where Do We Go from Here? 2016
2016 Open vs. Minimally Invasive Hysterectomy: Commercially Insured Costs and Readmissions 2016
2016 Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials 2016
2016 Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma 2016
2016 See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology? 2016
2016 Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes 2016
2016 HPV vaccines: Translating immunogenicity into efficacy 2016
2016 Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer 2016
2016 A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results 2016
2016 A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results 2016
2016 Cervical cancer screening: Evidence behind the guidelines 2016
2016 Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer 2016
2016 Reply 2016
2016 A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3) 2016
2016 Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study 2016
2016 Open vs. minimally invasive hysterectomy: Commercially insured costs and readmissions 2016
2016 The role of human papillomavirus testing after treatment for high-grade cervical dysplasia 2016
2015 Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients 2015
2015 Uterine sarcoma, version 1.2016: Featured updates to the NCCN Guidelines 2015
2015 Obesity and perioperative pulmonary complications in robotic gynecologic surgery 2015
2015 Cervical Cancer, Version 2.2015. 2015
2015 Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines 2015
2015 Immunoprevention of human papillomavirus-associated malignancies 2015
2015 Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance 2015
2015 Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening 2015
2015 Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer 2015
2015 A 9-valent HPV vaccine against infection and intraepithelial Neoplasia in women 2015
2015 In reply 2015
2015 Increased cervical cancer risk associated with screening at longer intervals 2015
2015 Laparoscopic fluorescent visualization of the ureter with intravenous IRDye800CW 2015
2015 Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial 2015
2015 Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance 2015
2015 Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance 2015
2014 Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ 2014
2014 Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV pseudovirions 2014
2014 A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women 2014
2014 Uterine neoplasms, version 1.2014 2014
2014 A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study 2014
2014 A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy 2014
2014 Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease 2014
2014 Black race independently predicts worse survival in uterine carcinosarcoma 2014
2014 Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer 2014
2014 Outcomes of gynecologic oncology patients undergoing robotic-assisted laparoscopic procedures in a university setting 2014
2014 Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma 2014
2014 Relevance of random biopsy at the transformation zone when colposcopy is negative 2014
2014 Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: Analysis of women in the control arm of the randomized, controlled PATRICIA trial 2014
2014 Tertiary prevention of cervical cancer 2014
2014 Update on vaccination clinical trials for HPV-related disease 2014
2013 Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observation 2013
2013 Erratum: HPV vaccination in women treated for CIN2/3: It's still all about prevention (Gynecologic Oncology (2013) 130 (255-256)) 2013
2013 Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer 2013
2013 HPV vaccination in women treated for CIN2/3: It's still all about prevention 2013
2013 In reply. 2013
2013 Recommendations for a national agenda to substantially reduce cervical cancer 2013
2013 Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins 2013
2013 Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine 2013
2013 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors 2013
2013 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors 2013
2013 Cervical cancer: Clinical practice guidelines in oncology 2013
2013 Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women 2013
2013 Optimization of Multimeric Human Papillomavirus L2 Vaccines 2013
2013 Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women 2013
2013 High-risk human papillomavirus detection in women with low-grade squamous intraepithelial lesions or higher-grade cytology using the cervista HPV HR test 2013
2013 Human papillomavirus: What every provider should know 2013
2013 Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors 2013
2012 New insights into cervical cancer screening 2012
2012 Survey of Robotic Surgery Credentialing Requirements for Physicians Completing OB/GYN Residency 2012
2012 Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: Retrospective pooled analysis of trial data 2012
2012 TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma 2012
2012 Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial 2012
2011 A multimeric L2 vaccine for prevention of animal papillomavirus infections 2011
2011 Capsomer vaccines protect mice from vaginal challenge with human papillomavirus 2011
2011 Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies 2011
2011 A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma 2011
2011 Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment 2011
2011 Adaptive data-driven inventory control with censored demand based on Kaplan-Meier estimator 2011
2011 Factors Associated with Intention to Vaccinate a Daughter against HPV: A Statewide Survey in Alabama 2011
2011 Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma 2011
2011 Invasive cervical cancer and screening: What are the rates of unscreened and underscreened women in the modern era? 2011
2011 Referral patterns and incidence of cervical intraepithelial neoplasia in adolescent and pregnant patients: The impact of the 2006 guidelines 2011
2010 Cervical cancer: Clinical practice guidelines in oncology 2010
2010 Robotic surgery in gynecologic oncology fellowship programs in the USA: A survey of fellows and fellowship directors 2010
2010 The changing face of cervical cancer screening in the United States 2010
2010 Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening 2010
2010 What is the role of HPV typing in the United States now and in the next five years in a vaccinated population? 2010
2010 Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus 2010
2010 Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women 2010
2010 How does public policy impact cervical screening and vaccination strategies? 2010
2009 An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC) 2009
2009 Introduction: Human Papillomavirus-A Clear, Present, and Common Danger 2009
2009 The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer 2009
2009 Comprehensive surgical staging for endometrial cancer in obese patients 2009
2009 Human papillomavirus infection 2009
2009 The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia 2009
2009 The management of cervical intraepithelial neoplasia during pregnancy: Is colposcopy necessary? 2009
2009 Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma 2009
2009 Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection 2009
2009 Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts 2009
2009 Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes 2009
2009 Early-stage endometrial cancer: Is adjuvant radiation really warranted? 2009
2009 Uterine neoplasms 2009
2008 A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer 2008
2008 Erratum: Evaluation of the interim analysis from the PATRICIA study group: Efficacy of a vaccine against HPV 16 and 18 (Expert Review of Anticancer Therapy (2008) vol. 8 (5) (701-705)) 2008
2008 Evaluation of the interim analysis from the PATRICIA study group: Efficacy of a vaccine against HPV 16 and 18 2008
2008 Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects 2008
2008 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects 2008
2008 Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001) 2008
2008 Pretreatment with cisplatin enhances E7-Specific CD8+ T-cell -mediated antitumor immunity induced by DNA vaccination 2008
2008 Age considerations when vaccinating against HPV 2008
2008 Initial lessons learned in HPV vaccination 2008
2008 Lynch syndrome in women less than 50 years of age with endometrial cancer 2008
2008 The future of vaccines for cervical cancer 2008
2008 Lipoxygenase pathway receptor expression in ovarian cancer 2008
2008 Cervical cancer 2008
2008 Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN 2008
2008 The current and future role of screening in the era of HPV vaccination 2008
2007 Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma [15] 2007
2007 Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: A retrospective university experience 2007
2007 Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multiinstitutional experience 2007
2007 A multi-institutional review of outcomes of endometrial stromal sarcoma 2007
2007 Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma 2007
2007 Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia 2007
2007 Clinical and pathologic correlates in surgical stage II endometrial carcinoma 2007
2007 New advances in vaccine technology and improved cervical cancer prevention 2007
2007 Diagnostic loop electrosurgical excisional procedure for discrepancy: Do preoperative factors predict presence of significant cervical intraepithelial neoplasia? 2007
2007 A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy 2007
2007 A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer [13] 2007
2007 LUMA™ cervical imaging system 2007
2007 Primary appendiceal cancer: Gynecologic manifestations and treatment options 2007
2007 Autoclave sterilization of instruments used on women with cervical neoplasia is an effective method of eradicating residual human papillomavirus DNA: A polymerase chain reaction-based evaluation 2007
2007 Gene expression profiling of women with varying degrees of cervical intraepithelial neoplasia 2007
2007 Treatment considerations in advanced endometrial cancer 2007
2006 A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer 2006
2006 Cervical intraepithelial neoplasia in adolescent women: Incidence and treatment outcomes 2006
2006 Therapeutic role of lymph node resection in endometrioid corpus cancer: A study of 12,333 patients 2006
2006 Bowel Resection at the Time of Primary Debulking for Epithelial Ovarian Carcinoma: Outcomes in Patients Treated with Platinum and Taxane-Based Chemotherapy 2006
2006 Novel methods to treat and prevent human papillomavirus infection 2006
2006 Hormonal contraception and false-positive cervical cytology: Is there an association? 2006
2006 Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients 2006
2006 Carcinosarcoma of the ovary - A case series 2006
2006 Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy" [2] (multiple letters) 2006
2005 Optical detection of cervical neoplasia: results from an internally-controlled multicenter study. 2005
2005 The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC) 2005
2005 A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses 2005
2005 Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report 2005
2005 A case report of rhabdomyosarcoma of the uterus associated with uterine inversion 2005
2005 A prospective evaluation of "see and treat" in women with HSIL Pap smear results: Is this an appropriate strategy? 2005
2005 Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis 2005
2005 Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy 2005
2005 What is the correct management of stage i upsc?: 0013 2005
2004 Evaluation of tissue-specific promoters in carcinomas of the cervix uteri 2004
2004 Protrusio acetabuli presenting as a complex pelvic mass after total hip arthroplasty 2004
2004 High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus 2004
2004 A double-blinded, randomized controlled trial of oxytocin at the beginning versus the end of the third stage of labor for prevention of postpartum hemorrhage 2004
2004 Immunohistochemical Evaluation of the c-kit Proto-oncogene in Sarcomas of the Uterus: A Case Series 2004
2004 HPV triage of patients with ASCUS cervical Pap smears 2004
2004 Optical detection of high-grade cervical intraepithelial neoplasia in vivo: Results of a 604-patient study 2004
2004 Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer 2004
2003 Human Papillomavirus Triage of Patients with Atypical Squamous Cells of Undetermined Significance on Cervical Papanicolaou Smear 2003
2003 Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy 2003
2003 Primary extrarenal rhabdoid tumor of the ovary: A case report 2003
2003 Complications of indwelling venous access devices in patients with gynecologic malignancies 2003
2003 Postmenopausal uterine inversion associated with endometrial polyps 2003
2003 Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy 2003
2002 Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture 2002
2002 Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. 2002
2002 Uterine leiomyosarcoma metastatic to the thyroid 2002
2002 Uterine leiomyosarcoma metastatic to the thyroid. 2002
2002 Immunotherapy of ovarian cancer 2002
2002 A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer 2002
2002 A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis 2002
2002 Conservative management of Stage I endometrial carcinoma after surgical staging 2002
2002 Gene therapy. 2002
2001 Gene therapy and cervical cancer: An overview 2001
2001 Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix 2001
2001 Endometrial carcinoma. 2001

Chapter

Year Title Altmetric
2018 Radical hysterectomy.  2136-2145. 2018
2014 A 38-year-old woman with heavy vaginal bleeding 6 months after D & C for complete mole.  282-284. 2014
2014 A 62-year-old woman with a vulvar lesion.  285-286. 2014
2014 A 64-year-old woman with ovarian cancer, emesis, and abdominal pain.  290-293. 2014
2014 A 65-year-old woman with new-onset fatigue, parasthesias, and muscle cramps after chemotherapy for ovarian cancer.  294-296. 2014
2013 Preinvasive disease of the lower genital tract.  129-150. 2013
2007 Prognostic markers of uterine papillary serous carcinoma.  217-224. 2007

Principal Investigator On

  • Addressing Emerging Health System Priorities in Cervical Cancer Prevention  awarded by University of British Columbia 2018 - 2023
  • UAB 1753 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer  awarded by University of Chicago 2018 - 2023
  • NLOCF Drive Out Ovarian Cancer Research Award  awarded by NORMA LIVINGSTON OVARIAN CANCER FOUNDATION 2017 - 2021
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2019 - 2020
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2018 - 2020
  • UAB Referral Colposcopy  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2018 - 2019
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer - Administrative Core  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer - Developmental Research Program  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer - Pilot Project: An Assessment of Immunogenicity in Adolescent Women receiving Gardasil, Gardasil 9, or Cervarix  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer - Project 1  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer - Project 2  awarded by Johns Hopkins University 2014 - 2019
  • SPORE in Cervical Cancer - Project 3  awarded by Johns Hopkins University 2014 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2017 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2018
  • Woman to Woman Program: Volunteer Mentoring Program for Newly Diagnosed Ovarian Cancer Patients  awarded by Ovarian Cancer Research Fund, Inc. 2015 - 2018
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Prevalence and Genotype Distribution of Cervical and Oral HPV Infection in HIV+Brazilian Women  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by ADVAXIS, INC. 2016 - 2017
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2016
  • Private Grant  awarded by AMGEN, INC. 2012 - 2016
  • Gynecologic Oncology Group Clinical Trials  awarded by GYNECOLOGIC ONCOLOGY GROUP 2012 - 2016
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2014 - 2015
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2013 - 2014
  • SPORE in Cervical Cancer - Project 1  awarded by Johns Hopkins University 2009 - 2014
  • SPORE in Cervical Cancer - Project 2  awarded by Johns Hopkins University 2009 - 2014
  • A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200  awarded by National Cancer Institute/NIH/DHHS 2008 - 2014
  • Development of an HPV Vaccine for Global Prevention of Cervical Neoplasia  awarded by American Cancer Society, Inc. 2008 - 2014
  • Private Grant  awarded by INTUITIVE SURGICAL 2012 - 2014
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2012 - 2013
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2011 - 2012
  • Private Grant  awarded by MERCK & COMPANY, INC. 2008 - 2011
  • Private Grant  awarded by ROCHE MOLECULAR SYSTEMS, INC. 2004 - 2011
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2010 - 2011
  • Private Grant  awarded by GlaxoSmithKline 2004 - 2010
  • UAB Referral Colposcopy Clinic  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH 2009 - 2010
  • Private Grant  awarded by MGI PHARMA, INC. 2005 - 2009
  • Investigator On

  • Private Grant  awarded by TESARO, INC. 2019 - 2024
  • Private Grant  awarded by CELSION CORPORATION 2018 - 2023
  • Private Grant  awarded by GENMAB 2018 - 2023
  • Private Grant  awarded by DECIPHERA PHARMACEUTICALS. LLC 2018 - 2023
  • Private Grant  awarded by TAPIMMUNE, INC. 2018 - 2023
  • Private Grant  awarded by AGENUS, INC. 2020 - 2023
  • Private Grant  awarded by Leap Therapeutics, Inc. 2017 - 2022
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2022
  • UAB 1788: Pilot Study of Daily Exemestane in Women with Complex Alypical Hyperplasia of The Endometrium / Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer (Fixed Price)  awarded by University of Wisconsin-Madison 2017 - 2021
  • UAB 1788; Pilot Study of Daily Exemestane in Women with Complex Alypical Hyperplasia of The Endometrium / Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer (Cost Reimbursable)  awarded by University of Wisconsin-Madison 2017 - 2021
  • Private Grant  awarded by TESARO, INC. 2016 - 2021
  • Neoadjuvant Chemotherapy Tumor Profiling in Ovarian Cancer: Genomic and Proteomic Analysis  awarded by NRG ONCOLOGY FOUNDATION 2016 - 2021
  • Private Grant  awarded by MATEON THERAPEUTICS, INC. 2016 - 2021
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015 - 2021
  • Private Grant  awarded by PLEXXIKON 2016 - 2021
  • Cervical Cancer Derived Xenografts (PDX) and Organoid Raft Cultures to Evaluate Pathway Specific Therapeutic Agents.  awarded by National Cancer Institute/NIH/DHHS 2019 - 2020
  • Private Grant  awarded by ABBVIE INC 2015 - 2020
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2020
  • Private Grant  awarded by CELSION CORPORATION 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Implementation of Direct-to-Patient Telemedicine Healthcare Initiatives  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2017 - 2019
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2019
  • CITY Health II - The Center for the Study of Community Health  awarded by National Center for Chronic Disease Prevention & Health Promo./CDC/DHHS 2014 - 2019
  • COMPLETED - SPORE in Cervical Cancer - Project 4  awarded by Johns Hopkins University 2014 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by Genentech 2017 - 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2018 - 2019
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2018 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • Private Grant  awarded by LICOR, INC. 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2018
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2016 - 2018
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2016
  • Private Grant  awarded by ONCOTHYREON, INC. 2015 - 2016
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2014 - 2016
  • Private Grant  awarded by Pfizer Pharmaceuticals 2012 - 2015
  • Private Grant  awarded by ASTRAZENECA AB 2014 - 2015
  • Private Grant  awarded by LEIDOS BIOMEDICAL RESEARCH, INC. 2013 - 2014
  • SPORE in Cervical Cancer  awarded by Johns Hopkins University 2009 - 2014
  • SPORE in Cervical Cancer - Project 4  awarded by Johns Hopkins University 2009 - 2014
  • Tissue Resource Site (TSS) in Support of the The Cancer Genome Atlas (TCGA) Program - Admin Core  awarded by SAIC - FREDERICK 2013 - 2014
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC. 2012 - 2014
  • A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer  awarded by American College of Radiology Imaging Network 2012 - 2014
  • Predictors of Survival Outcomes for Carcinosarcoma of the Female Genital Tract  awarded by University of Minnesota 2013
  • ACRIN 6682: Phase II Trial of 64 CU-ATSM PET/CT in Cervical Cancer (R09-186)  awarded by American College of Radiology 2010 - 2013
  • Private Grant  awarded by MORPHOTEK, INC. 2010 - 2013
  • Private Grant  awarded by MORPHOTEK, INC. 2011 - 2013
  • Private Grant  awarded by Genentech 2011 - 2013
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2011 - 2012
  • Zambian Cervical Cancer Research Capacity Initiative  awarded by National Cancer Institute/NIH/DHHS 2011 - 2012
  • Private Grant  awarded by DAIICHI SANKYO PHARMA DEVELOPMENT 2011 - 2012
  • Education And Training

  • Doctor of Medicine, Georgetown University 1995
  • New England Medical Center, Internship 1996
  • New England Medical Center, Residency 1999
  • UAB Hospital, Postdoctoral Fellowship 2002
  • Full Name

  • Warner Huh